

Department of Defense Drug Demand Reduction Program (DDRP)

Drug Testing Advisory Board Meeting *June 11, 2015*

COL Tom Martin, USA

Director, Drug Testing and Program Policy

Office of the Under Secretary of Defense for Personnel and Readiness

Personnel Risk Reduction



Personnel Risk Reduction (PRR) Office

The Personnel Risk Reduction (PRR) office:

Provides Drug Demand Reduction policy, direction, oversight and program analysis

Dialogues with the Military Services and other Governmental Agencies to further the Department's efforts to mitigate drug abuse and reduce counterproductive "high risk behaviors"



PRR Vision & Mission

The vision of our office is challenging but clear:


The Department must implement timely, effective policy initiatives and appropriate directives to drive down preventable mishaps and illicit drug abuse to zero

And our mission statement supports that vision:

Through the leadership of the 3-Star Safety and Occupational Health Steering Group and the Addictive Substance Misuse Advisory Committee foster, encourage, and facilitate policies, programs, and initiatives that identify, mitigate, and address counterproductive high risk behaviors



Personnel Risk Reduction





P&R Equities in Addressing Illegal Drug Use

- Drug abuse directly affects individual and unit readiness and is a safety issue
- Deterrence requires a realistic and substantive ability to detect drug abuse and hold accountable individuals who chose to abuse drugs. Drug abuse crosses all ages and ranks
 - Consumes limited resources
 - Significant loss to the Services Return on Investment
 - FY14 over 15,500 service members drug positive
- Ten years of military conflicts has generated a large population of injured Service members due to combat or training
 - Significant increase in the number and duration of opiate-base prescriptions issued (Oxycodone, Hydrocodone)
 - Substantial potential for dependency / addiction
 - Substantial problem in drug diversion sharing or "trading up"



DDRP Mission/Regulatory Guidance

• Mission:

- Deter illicit and prescription drug abuse by military service members and DoD civilian personnel in testing designated positions (TDPs) to maintain military readiness and safety
- Provide drug abuse prevention, education, and outreach services to military personnel and their families
- Identify new drugs of abuse entering the illicit drug culture and develop testing procedures to detect their use

Regulatory guidance is found in:

- DODI 1010.01 Military Personnel Drug Abuse Testing Program
- DODI 1010.09 DoD Civilian Employee Drug-Free Workplace Program
- DODI 1010.16 Technical Procedures for the Military Personnel Drug Abuse Testing Program
- Executive Order 12564--Drug-Free Federal Workplace



DDRP Driving Factors

- Drug abuse in the general U.S. 18-25 year old male group is estimated to be 17-20%— the population from which the Service recruits their enlisted personnel
- Before DoD instituted drug testing among Service personnel, drug use was a significant recurring problem
 - Vietnam (estimated over 5% of returning service members addicted to heroin)
 - 1981 CVN Nimitz aviation mishap 14 killed, 48 injured, 7 aircraft destroyed,
 11 aircraft damaged, \$150M in damages, six deceased with detectable levels of marijuana
- Notable increase in abuse/misuse of prescription pain medications
- Personnel abusing illicit drugs or prescription medications are a safety hazard resulting in the potential loss of equipment, resources, and lives




DDRP History

- Jun 11, 1971 President Nixon directed military drug urinalysis program to identify service members with drug addiction returning from Vietnam
- May 26, 1981 CVN Nimitz aviation mishap 14 killed, 48 injured, 7 aircraft destroyed, 11 air craft damaged, \$150M in damages. Six deceased service members with detectable levels of marijuana upon medical autopsy and toxicology analysis
- Dec 28, 1981 Deputy Secretary authorized use of drug positive urinalysis for punitive measures including courts martial and military separation
- 1984 Department of Defense issued DoD Directive 1010.1 that formally defined forensic drug testing requirements and responsibilities for testing
- September 15, 1986 President Reagan issued Executive Order 12564 mandating drug testing for all federal civilians
- 2010 Chairman, Joint Chiefs of Staff requested review and emphasis on program funding for expanded prescription drug testing for opiates and benzodiazepines




DoD Laboratories





Current Panel of Tested Drugs

- Marijuana (THC)
- Cocaine (BZE)
- Amphetamine & Methamphetamine
- Designer Amphetamines / Ecstasy
- Heroin
- Oxycodone/Oxymorphone
- Hydrocodone/hydromorphone
- Codeine/Morphine (100% Opiates Testing on 1 Oct 2012)
- Benzodiazepines: nordiazepam, oxazepam, temazepam, lorazepam, and α-OH alprazolam (100% on 1 Oct 2013)
- Synthetic Cannabinoids (December 16, 2013)
- Special request for unusual or novel drug testing conducted at Armed Forces Medical Examiners System





DoD Cutoffs

Screening (ng/mL)

Amphetamines	500
Cannabinoids	50
Cocaine	150
Opiates	300
Designer Amps	500
• 6-AM	10

- Oxycodone 100
- Hydrocodone 300
- Benzodiazepines 200
- Synthetic cannabinoids 10

Confirmation (ng/mL)

d-Amphetamine	100
• d-Methamphetamine	100
 THC metabolite 	15
 Benzoylecgonine 	100
Codeine	2,000
Morphine	4,000
MDMA/MDA	500
• 6-AM	10
Oxycodone	100
Oxymorphone	100
Hydrocodone	100
Hydromorphone	100
Benzodiazepines*	100

Synthetic cannabinoids 1

 ^{*}Lorazepam; Diazepam; Temazepam;
 Alpha-Hydroxy Alprazolam; Ozazepam



Current Situation


(Positive Drug Distribution)

~40% decrease in opiate positives, but prescription medication abuse cause for concern!

Unique Active Duty Positive Service Members	2009 (12,368)	2010 (10,790)	2011 (8,988)	2012 (8,837)	2013 (8,948)	2014 (7,948)
Marijuana	8,472	6,937	5,535	5,454	5,000	4,498
Cocaine	2,864	2,309	2,025	1,714	1,195	1,120
d-Amphetamine	993	976	971	973	899	752
d-methamphetamine	624	502	507	478	439	384
MDMA (Ecstasy)	804	751	415	154	150	148
MDA (Adam)	410	334	204	101	98	91
PCP	4	3	0	0	NT	NT
Codeine (39% testing in FY 2012)	118	104	104	144	209	158
Morphine (39% testing in FY 2012)	140	165	174	194	237	169
Oxycodone (35% testing in FY 2012)	250	402	305	485	775	439
Oxymorphone (35% testing in FY 2012)	485	746	604	840	1,368	784
Hydrocodone (39% testing in FY 2012)	NT	NT	NT	187	554	285
Hydromorphone (39% testing in FY 2012)	NT	NT	NT	232	622	334
Heroin	108	104	136	118	122	115
α-hydroxy-alprazolam (23% testing in FY 2013)	NT	NT	NT	NT	40	120
Lorazepam (23% testing in FY 2013)	NT	NT	NT	NT	13	63
Nordiazepam (23% testing in FY 2013)	NT	NT	NT	NT	33	90
Oxazepam (23% testing in FY 2013)	NT	NT	NT	NT	134	351
Temazepam (23% testing in FY 2013)	NT	NT	NT	NT	92	256




Overall Military Positive Rate





Positive Rate by Component





Synthetic Marijuana (Spice)

- "Spice" products present unique challenges
 - Large number of Spice drug variants that are continually changing
 - Requires a low cost automated screening procedures to facilitate large population random testing

DoD response

- Random testing started December 16, 2013
- 0.023 positive rate (similar to MDMA) in CY 2014

Adding five metabolites May 2015

- 5F-PB22
- MAM-2201
- AB-Chminaca
- AB-Fubinaca
- AB-Pinaca



Adjusting the Testing Panel

Rapid response to changing threat

- ecstasy, oxycodone/oxymorphone
- hydrocodone/hydromorphone
- benzodiazepines

Prevalence testing

- Results drive change
- Approved by OUSD(Personnel & Readiness)
- Short time frame (< 1 year)

Emerging synthetic drugs

- "Spice" Synthetic cannabinoids
- "Bath Salts" Synthetic cathinones / methamphetamine
- Supplement Additives



Automated MRO Review Process

- Compares positive result to the individual's military prescription record
- Implemented on May 1, 2012
- Decreased manual MRO process (MRO "Wash")
- Tricare/DoD pharmacy dependent
- FY 2014 Summary
 - Oxycodone = 78% (12,586 positives "washed")
 - Benzodiazepines = 67% (11,838 positives "washed")
 - Opiates = 46% (11,443 positives "washed")




DoD Agencies' Testing Results

FY	TDPs	TDPs	TDP	Applicants	Applicants	Applicant	Combined
	Tested	Positive	Positive Rate	Tested	Positive	Positive Rate	Positive Rate
2012	114,374	420	0.37	30,295	121	0.40	0.37
2013	117,041	443	0.38	24,146	97	0.40	0.38
2014	116,108	413	0.36	27,845	77	0.28	0.34






Laboratory vs. MRO Positives






Overall MRO Data by Drug






AMPHETAMINE






METHAMPHETAMINE






CODEINE





MORPHINE





In God We Trust, Everybody Else Must Pee In The Bottle

